Cullinan Therapeutics, Inc. (CGEM)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 1
Do Nothing: fundamentalScore is 2 (below the required floor of 3), so no fresh long is admissible regardless of the chart; the tape is broken anyway (10.28 below SMA20/50/200 and every short-term MA, MACD -1.44 expanding, ADX 30.3 rising on the decline), no breakout stop qualifies (nearest meaningful settled pivot 11.12 gives R/R 1.42 and the 12.41 swing high gives 0.80), and any pullback/oversold limit is countertrend (price < SMA50 15.87 with MACD < 0).
Company overview
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer in the United States. Its pipeline includes bispecific T cell engagers and small-molecule inhibitors in various phases of clinical trials. The company collaborates with partners for development and commercialization efforts.
Fundamental
weakCullinan Therapeutics is a pre-revenue biotech with a clean balance sheet but speculative, binary-risk prospects.
Pre-revenue clinical-stage biotech: zero revenue, roughly $200 million annual net loss and about $170 million of annual cash burn, offset by a debt-free balance sheet holding $313.8 million of cash and investments (about 47% of market cap) and a runway management describes as into 2029. The equity is a binary bet on a February 2027 zipalertinib PDUFA date and December 2026 CLN-978 autoimmune data. Financially clean but earnings-less and dilution-prone — speculative rather than distressed.
Sentiment
fairMedia sentiment is mildly positive but unchanged, with no immediate catalysts to shift the current outlook.
The one actionable catalyst is the 2026-11-10 Q3 2026 corporate update (announced; earnings; bullish on market reception) — nine-month net loss narrowing to $152.8M from $169.2M, $313.8M of cash and investments with runway into 2029, and a zipalertinib NDA initiated in first-line EGFR ex20ins NSCLC under FDA Real-Time Oncology Review — but it is five days old, only partially priced, and no dated forward catalyst sits inside the 30-day array. The sentiment delta is determinate and essentially flat to marginally cooler (scoring polarity_score ≈ +0.10 on 7 scored items versus baseline ≈ +0.22 on 6 scored items, both windows positive-scored), retail is indeterminate on a Reddit 403 access block, and the Red-Flag Screen is clean with no severe or moderate cap applied, leaving a mixed, forming setup rather than an actionable-now or a deteriorating one.
Technical
very weakThe stock is in a severe downtrend, trading below all major moving averages with no reversal signals.
Broken structure: at 10.28 CGEM trades below SMA20 (13.42), SMA50 (15.87), SMA200 (15.82), EMA9 (11.62), EMA21 (13.04), WMA9 (11.06), WMA21 (12.66) and DEMA14 (10.75), with only TEMA14 (10.29) at the price — a full bearish MA stack built by the 2026-11-04 (-21.9%) and 2026-11-05 (-12.6%) collapse from 15.75 to 10.80 and a further -7.7% on 2026-11-12. RSI14 30.60 and Williams %R -91.90 are deeply oversold but have produced no reversal bar and no positive divergence; MACD -1.44/-1.16 with histogram -0.28 is negative and widening, and ADX14 30.26 and rising with price under every average reads as a strong DOWN trend (ADX is direction-agnostic), not a coiled base. ATR14 1.16 is 11.28% of price, so any structure-derived stop sits inside a single normal session. Nothing here is a long setup; score 1. The trade is blocked upstream in any case: fundamentalScore 2 < 3.
You’re looking at 2026-11-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

